Jasper Therapeutics, Inc.
JSPR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001788028
No open-market purchases or sales by Jasper Therapeutics, Inc. insiders were filed in the last 90 days; 45 institutions reported holding it in 13F filings for Q2 2026, worth $5.05M in total; no superinvestor holds it.
Other share classesJSPRW
Q3 2021 vs. Q2 2021
How the institutions holding Jasper Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 0 | 9 | +9 |
| Shares | 0 | 10.3M | +10.3M |
| Value | $0 | $101.4M | +$101.4M |
New holders (9)
Institutions that held Jasper Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Abingworth LLP | 5,628,558 | $58.0M | 13.17% |
| Citadel Advisors LLC | 3,005,035 | $29.2M | 0.03% |
| Federated Hermes, Inc. | 1,500,000 | $12.5M | 0.02% |
| Morgan Stanley | 108,860 | $1.12M | 0.00% |
| Jane Street Group, LLC | 26,030 | $267.0K | 0.00% |
| Tudor Investment Corp Et Al | 20,000 | $205.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 8,953 | $92.0K | 0.00% |
| UBS Group AG | 539 | $6.00K | 0.00% |
| Royal Bank of Canada | 201 | $2.00K | 0.00% |
Sold out (0)
Institutions that held Jasper Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
None.